This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Propofol Cardioprotection for Type II Diabetics

This study has been completed.
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
University of British Columbia Identifier:
First received: August 12, 2008
Last updated: July 11, 2012
Last verified: July 2012
The purpose of this study is to determine if an intravenous anesthetic with antioxidant properties will protect the heart of diabetic patients from injury while undergoing coronary bypass surgery.

Condition Intervention Phase
Myocardial Injury Drug: Propofol Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: PRO-TECT II: Propofol Cardioprotection for Type II Diabetics

Resource links provided by NLM:

Further study details as provided by University of British Columbia:

Primary Outcome Measures:
  • Perioperative Plasma 15 f2t isoprostane, a biologically active marker of oxidative stress [ Time Frame: 24 hours post operation ]

Secondary Outcome Measures:
  • Perioperative (includes coronary sinus levels) plasma antioxidant concentration; ET-1, TNF alpha, Troponin I, peroxynitrite; gene and protein expression of eNOS and iNOS; hemodynamics [ Time Frame: 24 hours post operation ]

Enrollment: 137
Study Start Date: April 2005
Study Completion Date: June 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Propofol Cardioprotection
Drug: Propofol
Propofol cardioprotection : Ten minutes prior to initiation of CPB, we will stop delivery of isoflurane, inject 1 mg/kg iv and then continuously infuse propofol at 120µg/kg/min IV until 15 min after release of the aortic cross clamp (reperfusion).
Experimental: 2
Volatile Anesthesia Preconditioning
Drug: Propofol
Volatile Anesthetic preconditioning : Anesthesia will be maintained using an inspired concentration of isoflurane between 0.5-2% before, during, and after CPB, without administration of propofol. For ten minutes prior to the initiation of CPB we will deliver Isoflurane 2.5% end tidal then resume maintenance anesthesia as described.

  Show Detailed Description


Ages Eligible for Study:   19 Years to 29 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with and without Type II Diabetes Mellitus
  2. Hemodynamically Stable
  3. Non urgent Coronary Bypass Grafting utilizing Cardiopulmonary Bypass

Exclusion Criteria:

  1. Age less than 18 or greater than 80 years of age
  2. refuse informed consent
  3. Co-existing valvular heart disease
  4. Acute or evolving myocardial infarction
  5. hypersensitivity to propofol or formulation component
  6. Use of NSAIDs, Vitamins C or E within 5 to 7 days of surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00734383

Canada, British Columbia
UBC Dept of Anesthesiology, Pharmacology & Therapeutics, Vancouver Acute Hospital
Vancouver, British Columbia, Canada, V5Z 4E3
Sponsors and Collaborators
University of British Columbia
Canadian Institutes of Health Research (CIHR)
Principal Investigator: David M. Ansley, MD University of British Columbia
Study Director: Peter T. Choi, MD University of British Columbia
Study Director: David DY Chen, Ph.D University of British Columbia
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: University of British Columbia Identifier: NCT00734383     History of Changes
Other Study ID Numbers: H04-70456
Study First Received: August 12, 2008
Last Updated: July 11, 2012

Keywords provided by University of British Columbia:
coronary artery bypass surgery
coronary artery bypass grafting
cardiopulmonary bypass
myocardial injury markers,
sex differences
cardiac anesthesia
inhalational anesthetics

Additional relevant MeSH terms:
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Intravenous
Anesthetics, General
Anesthetics processed this record on June 22, 2017